TSS
VERV

Two Sigma Securities’s Verve Therapeutics VERV Stock Holding History

Two Sigma Securities’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-43,402
Closed -$487K – 2030
2025
Q2 		$487K Buy
+43,402
New +$247K 0.06% 445

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Two Sigma Securities's VERV Position: Q3 2025 in Review

Two Sigma Securities sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 43,402 shares — an estimated $487K sold.

Two Sigma Securities first reported a position in VERV in Q2 2025 and held it in 1 quarter. The position peaked at $487K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Two Sigma Securities reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Securities sold 43,402 Verve Therapeutics shares in Q3 2025, an estimated $487K.
  • Two Sigma Securities first reported a position in Verve Therapeutics in Q2 2025 and held it in 1 quarter.
  • Two Sigma Securities's Verve Therapeutics position peaked at $487K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.